NPHCNutra Pharma Corp.
Oct 15, 2026 — Capital Raise & Dilution Restructuring
Chart by TradingViewThe schedule
- Thu15Oct
Expected announcement of convertible debt restructuring or toxic share issuance to bridge the structural cash deficit from $0.00005.
- Wed17Feb
Q3 2026 financial update evaluating run-rate cash depletion and commercial OTC product revenues from $0.00002.
- Tue30Mar
Annual FY2026 going-concern assessment and probable reverse stock split authorization from a $0.00001 base.
- Wed19May
- Wed18Aug
Past
- Wed19Aug
Q2 2026 Earnings Release addressing critical cash burn and severe balance sheet deficits, with spot anchored at $0.0001.